arrow
E

Eliezer M. Van Allen

broad institute
H指数:112
被引数:8.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma

融合驱动致癌程序塑造重排型肾细胞癌的免疫景观

2026-08-260
OA
Distinct endogenous retroviruses are expressed in mutational subtypes of clear cell renal cell carcinoma and are linked to improved clinical outcomes

不同内源性逆转录病毒在透明细胞肾细胞癌的突变亚型中表达,并与改善的临床结局相关

2026-08-010
OAAI
Patient-partnered multiomics reveals the molecular architecture of angiosarcoma

患者合作多组学揭示血管肉瘤的分子架构

2026-07-240
OAAI
Disruption of microhomology-mediated end joining in Ewing sarcoma

破坏Ewing肉瘤中的微同源性介导末端连接

2026-07-210
OAAI
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial

吉西他滨和nab-紫杉醇联合或不联合VDR激动剂帕立骨化醇治疗转移性胰腺癌: 一项随机,多臂,磨合期试验

2026-05-250
PRE
UniversalEPI: robust prediction of cell type-specific and differential chromatin interactions from DNA sequence and chromatin accessibility

UniversalEPI: 基于DNA序列和染色质可及性稳健预测细胞类型特异性和差异性染色质相互作用

2026-05-210
OA
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial

卡铂联合或不联合纳武利尤单抗治疗转移性三阴性乳腺癌:一项随机II期试验

2026-05-160
OAAI
Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and BAP1 loss

单细胞表观遗传图谱揭示了一种与不良预后和BAP1缺失相关的ccRCC肿瘤内干扰素应答程序。

2026-02-200
OA
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity
2026-01-210
PRE
A context-augmented large language model for accurate precision oncology medicine recommendations

一种用于精准肿瘤学医学推荐的上下文增强大型语言模型

2026-01-150
OAAI
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer

早期激素受体阳性乳腺癌在抗PD-1和化疗治疗期间细胞的重编程

2025-11-280
OAAI
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

疗效、安全性及预测性生物标志物:nab-paclitaxel联合pembrolizumab治疗激素受体阳性乳腺癌的随机试点试验

2025-11-280
OAAI
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

比较性生存分析:激素敏感性转移性前列腺癌按疾病体积和转移时间划分——一项动态网络Meta分析

2025-11-040
PRE
Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma
2025-11-010
PRE
Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma

髓系细胞介导干扰素驱动的抗免疫疗法作用于晚期肾细胞癌

Immunity
IF26.3
2025-10-310
OAAI
fusion derived oncogenic programs shape the immune landscape in translocation renal cell carcinoma

融合衍生致癌程序塑造易位性肾细胞癌的免疫景观

2025-10-010
OAAI
Intratumoral viral transcriptomic signatures stratify immune phenotypes and clinical outcomes in renal cell carcinoma (RCC)

肿瘤内病毒转录组特征可区分肾细胞癌(RCC)的免疫表型和临床结局

2025-10-010
OAAI
Tamoxifen induces PI3K activation in uterine cancer

他莫昔芬诱导子宫癌中PI3K的激活

2025-08-220
OAAI